Lightnews — Scholar-powered news

Paul Bröckelmann

@broeckelmann.bsky.social

140 followers 54 following 60 posts

Physician Scientist in Cologne, interested in Hemato-Oncology, Lymphoma & Immunotherapy. Views are mine & no advise, repost/like no endorsement. COI: http://bit.ly/34MaLOt

bit.ly

Posts Media Videos Starter Packs

Pinned

Paul Bröckelmann @broeckelmann.bsky.social · May 27

Great to see my Commentary entitled "Hodgkin lymphoma: Great progress but room for improvement" published in the current issue of Nature Reviews Clinical Oncology
@natrevclinonc.nature.com Open Access Link: shorturl.at/YHOAn

1 8

Reposted by Paul Bröckelmann

Waggoner Lab @labwaggoner.bsky.social · 5h

A next-generation anti-CTLA-4 probody (folding the Fab fragment of the antibody in a tumor-associated protease-based manner) mitigates toxicity and enhances anti-tumor immunity in mice @natcomms.nature.com
www.nature.com/articles/s41...

1 5

Reposted by Paul Bröckelmann

Waggoner Lab @labwaggoner.bsky.social · 3d

IFNγ-producing PD-1+ T cells are a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving immune checkpoint inhibitor therapy @lunduniversity.bsky.social
www.nature.com/articles/s44...

1 4

Reposted by Paul Bröckelmann

Waggoner Lab @labwaggoner.bsky.social · 8d

Eomes controls the acquisition of regulatory and cytotoxic function in CD4+ T cells that are critical for limiting immune toxicity, while maintaining persistence and tumor control after immunotherapy @cp-immunity.bsky.social
www.cell.com/immunity/ful... @fredhutch.org

4 9

Reposted by Paul Bröckelmann

The Lancet @thelancet.com · 15d

Cancer deaths expected to rise to over 18 million in 2050—an increase of nearly 75% from 2024, study forecasts.

Explore the data ▶️ tinyurl.com/5n7dfnws @ihmeuw.bsky.social #NCDs

Figure: Global age-specific cancer (A) incidence and (B) mortality in 2023 for all sexes combined. Results are presented by 5-year age group. Left panels present age-specific incidence and mortality rates. Right panels present age-specific new case and death proportions. Copyright: 2025 Elsevier Ltd. All rights are reserved.

16 16

Paul Bröckelmann @broeckelmann.bsky.social · Sep 10

Congrats to my colleagues @unicologne.bsky.social, @uniklinikkoeln.bsky.social and @mpiage.bsky.social on their exciting study revealing functional synapses between neurons and small cell lung cancer. Out today @nature.com

Waggoner Lab @labwaggoner.bsky.social · Sep 10

Following malignant transformation, small cell lung cancer cells hijack neuronal synaptic signaling to promote tumor growth @nature.com
@stanforduniversity.bsky.social
www.nature.com/articles/s41...
@unicologne.bsky.social www.nature.com/articles/s41...

1 4

Paul Bröckelmann @broeckelmann.bsky.social · Sep 3

Excited to share our preprint on the new HaJo cell line and robust systemic PDX in vivo model includin comprehensive characterization to enable further research in rare non-MCL B-cell lymphoma with CCND1 re-arrangement: www.biorxiv.org/content/10.1...
@mpiage.bsky.social @uniklinikkoeln.bsky.social

2 2

Reposted by Paul Bröckelmann

NEJM.org @nejm.org · Sep 1

A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR T-cell therapy. Read the full case details: nej.md/41fYX4v

#MedSky #Hematology #Genetics

A graph showing the longitudinal variant allele frequency determined by whole-genome sequencing from the stem-cell product, peripheral-blood mononuclear cells (PBMC) before CAR T-cell therapy, and isolated peripheral-blood tumor cells

4 10

Paul Bröckelmann @broeckelmann.bsky.social · Aug 26

Honoured to have contributed a @bloodjournals.hematology.org Commentary (doi.org/10.1182/bloo...) on a recent study by @drmiguelperales.bsky.social @mskcancercenter.bsky.social highlighting improved outcomes with alloSCT in r/r cHL after prior ICI exposure (doi.org/10.1182/bloo...)

1 5

Paul Bröckelmann @broeckelmann.bsky.social · Aug 26

Longitudinal measurement of serum TARC shows rapid early cHL response to first-line nivolumab monotherapy and N-AVD. Potential to guide individualized immunotherapy? Great collaboration with W. Plattel @rug.nl now published @hemasphere-journal.bsky.social: onlinelibrary.wiley.com/doi/epdf/10....

Paul Bröckelmann @broeckelmann.bsky.social · Aug 25

Great to see the results of a joint NLG x GHSG academic phase 2 trial @hemasphere-journal.bsky.social: First-line treatment with B-CAP is feasible and effective in older patients with advanced-stage cHL, with improvement of most patient-reported HRQoL domains onlinelibrary.wiley.com/doi/10.1002/...

1 2

Reposted by Paul Bröckelmann

ESMO - European Society for Medical Oncology @myesmo.bsky.social · Aug 5

📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines

🔗 buff.ly/2ZYJc2c

3 7

Reposted by Paul Bröckelmann

Waggoner Lab @labwaggoner.bsky.social · Aug 1

Review @cp-med.bsky.social
Immune-related adverse events associated with cancer immunotherapy
www.cell.com/med/abstract...

This review explores immune-related toxicities arising from the major immunotherapy classes. By comparing mechanisms, risk factors, and management strategies across therapeutic platforms, the authors ...

www.cell.com

2 8

Reposted by Paul Bröckelmann

NEJM.org @nejm.org · Jul 30

In a patient with pathogenic ZAP70 mutations and HPV19-integrated SCC, restoring T-cell receptor signaling by stem-cell transplantation resolved HPV-related disease, revealing a direct oncogenic role for β-HPV in immunodeficiency. Read the Brief Report: nej.md/4lTiTCC

#MedSky

A photo showing the clinical course of verruca vulgaris and flat warts on the left hand before and after HCT

3 10

Paul Bröckelmann @broeckelmann.bsky.social · Jul 24

In summary, 4-6x PET-guided BrECADD is a new EMA-approved treatment option for AS-cHL patients 60-75 years of age. As also recently published in the JCO, 6x N-AVD shows exceptional benefit over 6x Bv-AVD in older S1826 patients with 2y PFS of 89%. Great to have two excellent options to choose from.

Paul Bröckelmann @broeckelmann.bsky.social · Jul 24

The 2-year PFS (91.5%) and OS after 4-6x BrECADD are unprecedented and indicate the high curative potential of an intensified approach in this historically challenging subgroup. Best outcomes in 60-65 years, more dose level reductions in frail patients.

Paul Bröckelmann @broeckelmann.bsky.social · Jul 24

Individual patient trajectories indicate short and anthracycline-sparing treatment with 4x BrECADD in 2/3 of the patients (PET2-negative), while also PET2-positive patients are able to achieve PET-negativity at EOT and favorable long-term outcomes. Improved QoL and Fatigue after 4-6x BrECADD.

Paul Bröckelmann @broeckelmann.bsky.social · Jul 24

Toxicity was mainly hematologic with associated febrile neutropenia (55%), infections, mucositis and gastrointestinal disorders. PNP of mostly grade 1 occurred in 40% No treatment-related mortality was reported. Most symptoms remained stable on and improved after BrECADD (as did functioning scales)

Paul Bröckelmann @broeckelmann.bsky.social · Jul 24

The HD21 Older Cohort was an international, multicenter single-arm phase 2 add-on to the randomized HD21 trial and recruited N=83 evaluable patients. 89% of patients received target no. of 4 or 6 cycles, with frequent use of per-protocol defined dose reductions.

Paul Bröckelmann @broeckelmann.bsky.social · Jul 24

Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social 🎉 Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options 🧵👀👇

2 1 2

Reposted by Paul Bröckelmann

Nature Metabolism @natmetabolism.nature.com · Jul 14

#NatMetabPicks | In Cancer Discovery @aacrjournals.bsky.social, L Zitvogel, C Bigenwald et al (@gustaveroussy.fr)

Oral supplementation with Akkermansia spp. Improves the efficacy of CAR-T cells against B cell lymphoma.

🧪

aacrjournals.org/cancerdiscov...

Gut microbiota modulation through Akkermansia spp. supplementation increases CAR-T cell potency

Abstract. This study investigates the clinical relevance of the gut microbiome at taxonomic and metabolic levels in anti-CD19 CAR-T cell therapy, both in patients and in a preclinical syngeneic tumor ...

aacrjournals.org

2 6

Reposted by Paul Bröckelmann

Waggoner Lab @labwaggoner.bsky.social · Jul 18

By integrating multi-dimensional data with deep learning, a new method known as ImmuScope predicts both MHC-II presentation and T helper cell immunogenicity @natmachintell.nature.com
www.nature.com/articles/s42...
www.nature.com/articles/s42...

1 7

Reposted by Paul Bröckelmann

Blood Journals' Portfolio @bloodjournals.hematology.org · Jul 14

Structural variations disrupting the 3’-UTR of PD-L1 and high PD-L1 expression were related with response to this combination therapy. buff.ly/9mWJEMH #hemesky

1 1

Paul Bröckelmann @broeckelmann.bsky.social · Jul 11

Really good to see improved gonadal function recovery and child birth rates after 4-6x BrECADD vs eBEACOPP in advanced-stage HL. Results now published are further supporting BrECADD as preferred treatment: @thelancetoncol.bsky.social doi.org/10.1016/S147... Congrats to the international HD21 team.

Reposted by Paul Bröckelmann

Waggoner Lab @labwaggoner.bsky.social · Jul 9

Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy @jci-insight.bsky.social
insight.jci.org/articles/vie...

2 9

Paul Bröckelmann @broeckelmann.bsky.social · Jul 8

3-year follow-up of TRANSFORM @ascocancer.bsky.social confirms significantly improved PFS with lisocel compared to SOC as second-line treatment for r/r LBCL (51% vs 26%): ascopubs.org/doi/10.1200/... PRO indicate improved HRQoL incl. Fatigue on treatment with lisocel, but similar long-term outcomes.

1 1 1